HROW241018P48000
- 0.50
- 0.000.00%
Harrow Newsroom
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $73
Harrow Health: Promising Growth Trajectory and Compelling Investment Opportunity
B. Riley Adjusts Price Target on Harrow to $73 From $50, Maintains Buy Rating
Express News | Harrow Inc - FDA Agrees to Melt-300 Phase 3 Special Protocol Assessment
Express News | Harrow Inc - Topline Readout Expected in Q4 2024
Express News | Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Belite Delights Investors, Soleno, ADMA, Harrow Deliver Triple-digit Gains, Keep An Eye On Oculis
Ophir Asset Management's Strategic Reduction in Harrow Inc Holdings
Harrow Announces Relaunch of TRIESENCE for Vitrectomy Visualization, Inflamation
Harrow Is Maintained at Buy by Lake Street
The Analyst Landscape: 4 Takes On Harrow
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $55
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $65
Express News | Harrow, Inc. : Craig-Hallum Raises Target Price to $65 From $45
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
Harrow +8%, Relaunches FDA-approved Triesence, Shares Climb
Harrow, Inc. (HROW): A Bull Case Theory
Express News | Harrow Inc: Expansion to Create Nearly 150 New Jobs in Nashville
Harrow Announces Nashville Expansion